De novo CD5 positive diffuse large B-cell lymphomas with bone marrow involvement in Korean

Journal of Korean Medical Science

Volumn 19, Issue 6, 2004, Pages 815-819

  Kong, Sun Young ^a,b   Cho, Eun Hae ^a   Woo, Hee Yeon ^a   Park, Qeuhn ^a   Ko, Young Hyeh ^a   Kim, Sun Hee ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

Antigens, CD5; Leukemia, Lymphocytic, Chronic; Lymphoma, Large Cell, Diffuse; Lymphoma, Mantle Cell

Indexed keywords

CD20 ANTIGEN; CD23 ANTIGEN; CD5 ANTIGEN; CYCLIN D1; LYMPHOCYTE MEMBRANE IMMUNOGLOBULIN;

ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; BONE MARROW METASTASIS; CANCER DIAGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DISEASE COURSE; FEMALE; GENE REARRANGEMENT; HUMAN; KOREA; LARGE CELL LYMPHOMA; LYMPHOID CELL; MALE; MANTLE CELL LYMPHOMA; NUCLEOLUS; ONSET AGE; PATHOPHYSIOLOGY; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION;

EID: 12144252352     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2004.19.6.815     Document Type: Article

References (21)

1. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November, 1997. Hematol J 2000; 1: 53-66.
2. Ko YH, Kim CW, Park CS, Jang HK, Lee SS, Kim SH, Ree HJ, Lee JD, Kim SW, Huh JR. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer 1998; 83: 806-12.
3. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780-95.
4. Yamaguchi M, Ohno T, Oka K, Taniguchi M, Ito M, Kita K, Shiku H. De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. Br J Haematol 1999; 105: 1133-9.
5. Yamaguchi M, Seto M, Okamoto M, Ichinohasama R, Nakamura N, Yoshino T, Suzumiya J, Murase T, Miura I, Akasaka T, Tamara J, Suzuki R, Kagami Y, Hirano M, Morishima Y, Ueda R, Shiku H, Nakamura S. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002; 99: 815-21.
6. Matolcsy A, Chadburn A, Knowles DM. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct. Am J Pathol 1995; 147: 207-16.
7. Pileri SA, Dirnhofer S, Went P, Ascani S, Sabattini E, Marafioti T, Tzankov A, Leoncini L, Falini B, Zinzani PL. Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology 2002; 41: 482-509.
8. Katzenberger T, Lohr A, Schwarz S, Dreyling M, Schoof J, Nickenig C, Stilgenbauer S, Kalla J, Ott MM, Muller-Hermelink HK, Ott G. Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell. Blood 2003; 101: 699-702.
9. Colomo L, Lopez-Guillermo A, Perales M, Rives S, Martinez A, Bosch F, Colomer D, Falini B, Montserrat E, Campo E. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78-84.
10. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol 2001; 13: 325-34.
11. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-49.
12. Mitelman F. ISCN 1995: An International System for Human Cytogenetic Nomenclature. S. Karger, Basel, Switzerland.
13. Cro L, Guffanti A, Colombi M, Cesana B, Grimoldi MG, Patriarca C, Goldaniga M, Neri A, Intini D, Cortelezzi A, Maiolo AT, Baldini L. Diagnostic role and prognostic significance of a simplified immunophenotypic classification of mature B cell chronic lymphoid leukemias. Leukemia 2003; 17: 125-32.
14. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirov J, Neuberg DS, Lander ES, Aster JC, Golub TR. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68-74.
15. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-47.
16. Pospisil R, Fitts MG, Mage RG. CD5 is a potential selecting ligand for B cell surface immunoglobulin framework region sequences. J Exp Med 1996; 184: 1279-84.
17. Kobayashi T, Yamaguchi M, Kim S, Morikawa J, Ogawa S, Ueno S, Suh E, Dougherty E, Shmulevich I, Shiku H, Zhang W. Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas. Cancer Res 2003; 63: 60-6.
18. Yin Z, Giacomello E, Gabriele E, Zardi L, Aota S, Yamada KM, Skerlavaji B, Doliana R, Colombatti A, Perris R. Cooperative activity of alpha4beta1 and alpha4beta7 integrins in mediating human B-cell lymphoma adhesion and chemotaxis on fibronectin through recognition of multiple synergizing binding sites within the central cell-binding domain. Blood 1999; 93: 1221-30.
19. Terol MJ, Lopez-Guillermo A, Bosch F, Villamor N, Cid MC, Campo E, Montserrat E. Expression of beta-integrin adhesion molecules in non-Hodgkin's lymphoma: correlation with clinical and evolutive features. J Clin Oncol 1999; 17: 1869-75.
20. Corcoran LM, Karvelas M, Nossal GJ, Ye ZS, Jacks T, Baltimore D. Oct-2, although not required for early B-cell development, is critical for later B-cell maturation and for postnatal survival. Genes Dev 1993; 7: 570-82.
21. Rutella S, Rumi C, Di Mario A, Leone G. Expression of thrombospondin receptor (CD36) in chronic B-cell lymphoproliferative disorders: a role in tumor metastasis? Eur J Histochem 1997; 41 (Suppl 2): 53-4.